CN104042564A - 一种应用于治疗干眼的他克莫司滴眼液 - Google Patents

一种应用于治疗干眼的他克莫司滴眼液 Download PDF

Info

Publication number
CN104042564A
CN104042564A CN201310081493.1A CN201310081493A CN104042564A CN 104042564 A CN104042564 A CN 104042564A CN 201310081493 A CN201310081493 A CN 201310081493A CN 104042564 A CN104042564 A CN 104042564A
Authority
CN
China
Prior art keywords
tacrolimus
dry eyes
treatment
xerophthalmia
eye drop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310081493.1A
Other languages
English (en)
Inventor
周世有
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhongshan Ophthalmic Center
Original Assignee
Zhongshan Ophthalmic Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongshan Ophthalmic Center filed Critical Zhongshan Ophthalmic Center
Priority to CN201310081493.1A priority Critical patent/CN104042564A/zh
Publication of CN104042564A publication Critical patent/CN104042564A/zh
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明为应用浓度为0.02%~0.03%的他克莫司治疗干眼,为一种针对干眼的新型治疗方法。针对目前临床上尚未有有效治疗干眼的治疗方法的现状,本方法旨在提供一种有效,低副作用的治疗干眼的措施。具体为应用浓度为0.02%~0.03%的他克莫司,每天四次,持续一个月,治疗慢性非干燥综合征相关性干眼。

Description

一种应用于治疗干眼的他克莫司滴眼液
发明领域
本发明专利涉及一种治疗方法,具体为局部应用约为0.02%~0.03%他克莫司治疗干眼 
发明背景 
最新的研究表明,他克莫司具有显著的抗炎效果,而在于眼的发病过程中炎症则扮演着一个重要角色。另外他克莫司的同类药环孢霉素A已经通过美国FDA的批准应用于干眼的治疗,而相对于环孢霉素A,他克莫司具有更强的抗炎效果,并且具有较小的副作用,目前仍然未有他克莫司治疗干眼的报道,故考虑将其应用于干眼的治疗。 
发明内容
本发明专利需要解决的问题是,针对目前对干眼的治疗尚无特别有效的治疗方法的现状,提供一种副作用小,疗效显著的干眼治疗方案。 
按照本方案的这个目的,为慢性非干燥综合征相关性干眼的患者提供一种新的治疗方案。 
具体制备方案:称取重量为25mg的他克莫司,用8~12.5毫升的含有山梨醇,乙醇等成分的溶剂将他克莫司的浓度调整到0.02%~0.03%。 
具体的治疗方案是:制备浓度0.02%~0.03%的他克莫司滴眼剂,治疗慢性非干燥综合征相关性干眼,每天四次,持续一个月。 
附图说明
图1是用0.02%~0.03%他克莫司治疗小鼠干眼模型1个月以后眼表的荧光素钠染色的图(评估干眼用) 
图2是用生理盐水治疗治疗小鼠干眼模型1个月以后眼表的荧光素钠染色的图(评估干眼用) 
图3是用0.02%~0.03%他克莫司及生理盐水治疗小鼠干眼模型1个月以后眼表的荧光素钠染色评分(分数高反应干眼严重)示意图(他克莫司用药4周后对干眼的治疗作用)。 
实施例
制备浓度为0.02%~0.03%的他克莫司。 
选取30只CBA/J小鼠,泪腺内注射肉毒杆菌素(20mU/50mL)诱导小鼠干眼模型。诱导干眼模型3天以后将30只小鼠随机平均分为两组,一组给予生理盐水滴眼,一天四次,作为对照 组,另一组给予0.02%~0.03%他克莫司滴眼,一天四次,作为实验组,实验进行一个月。每隔7天评估眼表干眼状态。一个月后,眼表荧光素钠染色评分结果显示应用他克莫司后干眼状态明显改善。 
附表 
暂无。 

Claims (4)

1.一种针对干眼的治疗方法,包含给药方式、治疗药物和适应征。其特征在于所述的给药方式为眼部滴用眼药水(1),所述的治疗药物为他克莫司(2),所述的适应证为干眼(3)。 
2.如权利1所述的治疗方法,其特征在于所述的眼部滴用眼药水(1)为一天四次(1-1),持续一个月(1-2)。 
3.如权利1所述的治疗方法,其特征在于所述的他克莫司(2)的浓度为0.02%~0.03%(2-1)。 
4.如权利1所述的治疗方法,其特征在于所述的干眼(3)为慢性(3-1)非干燥综合症相关性干眼(3-2)。 
CN201310081493.1A 2013-03-14 2013-03-14 一种应用于治疗干眼的他克莫司滴眼液 Pending CN104042564A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310081493.1A CN104042564A (zh) 2013-03-14 2013-03-14 一种应用于治疗干眼的他克莫司滴眼液

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310081493.1A CN104042564A (zh) 2013-03-14 2013-03-14 一种应用于治疗干眼的他克莫司滴眼液

Publications (1)

Publication Number Publication Date
CN104042564A true CN104042564A (zh) 2014-09-17

Family

ID=51496296

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310081493.1A Pending CN104042564A (zh) 2013-03-14 2013-03-14 一种应用于治疗干眼的他克莫司滴眼液

Country Status (1)

Country Link
CN (1) CN104042564A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108383856A (zh) * 2018-05-25 2018-08-10 中国医学科学院生物医学工程研究所 他克莫司纳米晶及其人工泪液复合物与制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101780076A (zh) * 2009-01-15 2010-07-21 鲁南制药集团股份有限公司 一种含有他克莫司的药物组合物用于干眼症治疗的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101780076A (zh) * 2009-01-15 2010-07-21 鲁南制药集团股份有限公司 一种含有他克莫司的药物组合物用于干眼症治疗的用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108383856A (zh) * 2018-05-25 2018-08-10 中国医学科学院生物医学工程研究所 他克莫司纳米晶及其人工泪液复合物与制备方法

Similar Documents

Publication Publication Date Title
CN100571707C (zh) 含有海藻糖的关节腔内注射给药制剂
HRP20191919T1 (hr) Donori nitroksila sa poboljšanim terapijskim indeksom
AU2016202421B2 (en) Method of treating neurological conditions with cardiac glycosides
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
MX2019007779A (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).
HRP20180071T4 (hr) Upotreba kladribina u liječenju očnog neuromijelitisa
PH12014501579A1 (en) Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers
RU2014103543A (ru) Ботулотоксины для применения в способе лечения жировых отложений
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
MX342020B (es) Apolipoproteina a-iv como un peptido antidiabetico.
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
BR112014031306A2 (pt) composição farmacêutica e respectivos usos
CN104042564A (zh) 一种应用于治疗干眼的他克莫司滴眼液
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
EA201100682A1 (ru) Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
RU2007141393A (ru) Способ лечения спастического и болевого синдромов у пациентов с последствиями позвоночно-спинномозговой травмы
RU2013142835A (ru) Способ лечения ишемического инсульта
BR112018008893A8 (pt) método para tratamento ou amenização de sintomas em um indivíduo com uma doença associada a um nervo craniano em particular, e composição farmacêutica óptica
UA111785C2 (uk) Композиція для лікування бородавок та спосіб лікування бородавок

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140917